Asset profile
BPI-7711
Small molecule
Evidence outlook · registrational
Non-Small Cell Lung Cancer: registrational readout pending
Entered Phase 3 on weak signal mid-stage evidence. No upcoming registrational readout date is posted to the registry — check News for topline announcements.
NCT03812809: The trial was an open-label, single-arm study of 226 patients receiving BPI-7711, with no randomized control group for comparison. Its primary endpoint was objective response rate by independent RECIST 1.1 review, but results were not posted, so no primary endpoint result can be assessed.
How the evidence outlook works ↗
Featured trials
Unlock featured-trial analysis
Research includes the instrumental studies, endpoints, key results, design grades, rationales and source links behind the Outlook.
Upcoming events
No upcoming readouts on record for this asset.
All registered studies
Unlock the complete ClinicalTrials.gov registry
Research includes every linked study, indication filters, phase grouping and featured-trial cross-links.
Competitive landscape
Unlock the competitor landscape
Research compares assets by shared mechanism and indication, including each competitor's stage in the relevant market.